9705256-7
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/045 — A1

(11) International Publication Number: WO 96/40092

(43) International Publication Date: 19 December 1996 (19.12.96)

(21) International Application Number: PCT/GB96/01368

(22) International Filing Date: 7 June 1996 (07.06.96)

(30) Priority Data:
08/487,627 — 7 June 1995 (07.06.95) — US
9604221.3 — 28 February 1996 (28.02.96) — GB

(71) Applicant *(for all designated States except US)*: THE HOWARD FOUNDATION [GB/GB]; Whitehill House, Granhams Road, Great Shelford, Cambridge, Cambridgeshire CB2 5JY (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HOWARD, Alan, Norman [GB/GB]; Whitehill House, Granhams Road, Great Shelford, Cambridge, Cambridgeshire CB2 5JY (GB). LANDRUM, John, Thomas [US/US]; Dept. of Chemistry, Florida International University, University Park, Miami, FL 33199 (US). BONE, Richard, Andrew [US/US]; Dept. of Physics, Florida International University, University Park, Miami, FL 33199 (US).

(74) Agent: HEPWORTH LAWRENCE BRYER & BIZLEY; Merlin House, Falconry Court, Bakers Lane, Epping, Essex CM16 5DQ (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICALLY ACTIVE CAROTENOIDS



(57) Abstract

The carotenoids lutein and zeaxanthin are disclosed for pharmaceutical use in the treatment of advanced macular degeneration. High dosages are deployed to produce the high serum carotenoid levels needed to cause take-up by the macula.